Replies to post #80815 on Avid Bioservices Inc (CDMO)

[entdoc]

hey freethemice,sunstar,rrdog,mojojo, Jonson, and all you on the "biological" side of the reality equation (rather than numbers crunchers), thanks for making the board a most interesting site. Actually, I read most posts, and think all of you are good writers. Don't always thank you, but appreciate the effort. CJ especially. Targeted therapy? PPHM has it. Conjugates? Old hat at PPHM. Got MABS!!?? OMG, aplenty. PPHM has an FDA manufacturing unit, AVID, to cook them. Not easy. All this tech PPHM is good at moving forward onstage, and now in the New York Times. Why, everyone SHOULD know by now that PPHM has silos full of targeted MAB rocket winners, the next anti-cancer drugs that will move us closer to the goal of converting cancer into a chronic disease like, say diabetes, arthritis, or hypertension. Where's the bandwagon?

[sunstar]

Accelerated Approval for bavi 2nd-line NSCLC means money, to some extent, as the marketing kicks in. That will help in funding the phase 3 trial and other operational needs. As RRdog wrote: "PPHM has many ways to finance other than ATM if they need more time." Commercial sales of bavi will be important for the company. I don' really expect that Peregrine will not obtain the deal they're seeking in negotiations with BPs, if bavi receives an AA from the FDA .

Aside from money issues, I'm quite looking forward to just seeing the data from the multiple cancer trials/ISTs. For instance: Bavi plus carboplatin plus pemetrexed against NSCLC, and Bavi plus Gemcitabine against Pancreatic cancer: Really, all of them.

sunstar